The way the world has been forced to change amid the Covid-19 pandemic is likely to have a lasting impact on the way we live our lives even when the lockdown restrictions are lifted. In this new economic and social environment, how can the renewable energy and battery sector prosper?
As part of The Next 100 Days guide, which identifies the key IP issues that businesses should be focussing on right now, we look at the topic of Crown Use and how it might impact on innovators in the wake of the pandemic.
Emmy Hunt and Edwina Fitzhugh summarise the most recent High Court decision. Sky v SkyKick, C-371/18, 29th April 2020.
The Court of Justice of the EU has handed down its judgment in Royalty Pharma (C-650/17) on the interpretation of Art. 3(a) of the EU’s Regulation on Supplementary Protection Certificates.
As businesses around the world face difficult operational challenges on multiple fronts, this guide is designed to help you to align your shifting commercial goals with an effective approach to intellectual property.
Genentech applied for an SPC in February 2007 to cover the compound Ranibizumab. Ranibizumab is a key constituent of the drug Lucentis which treats “wet” macular degeneration - an eye condition, which causes age-related vision loss.